NASDAQ:CELG Celgene Corporation
The name of Celgene corporation tells that it focuses on research and therapy of cancer. Its therapies are based on drugs or cells. Many have already been approved (European Commission recently approved azacitidine) but much more are still on trial or in development. Research centres are in Redford, CA, Seville, Spain, Warren, NJ, Sand Diego and San Francisco, CA.
Another focus area are inflamatory diseases. Apremilast is the Celgene’s first approved substance that inhibits inflamation; it is now searching for new ones.
Kinase inhibitors are an important part of Celgene’s work. They prevent kinases from turning genes on and off, which is those proteins’ task, if that could cause or worsen a disease. This corporation has merits for a great part of kinase inhibitors existing today.
Discovery of kinases is a part of a relatively young field called epygenetics. It studies environmental factors that influence expression of genes. This can be reversed; a key to some cure for some diseases including cancer could be here. Some epigenetic medications already exist. Celgene plans to search for one for a rare form of leukemia.
It is conducting or sponsoring hundreds of clinical trials at the moment and supports biomarker research which could help discover in advance whether certain patient is likely to benefit from propsed treatment.
Targeted covalent drugs are expected to completely silence disease-causing proteins by binding to them for the rest of the proteins’ existence while some existing drugs only stop them for some time. Not even mutation of those proteins, which is common in viral diseases and cancer, will be able to stop them. Targeting will be improved with this type of medication so therapy will hopefully be more efficient and have less side effects.
Celgene is involved with one of the new revolutionary findings: stem cells that can develop in any cell. Scientists hope those cells will some day be used to grow new tissues for people who have their old tissues damaged. They have to be harvested at birth from blood and tissue and can be stored for life.
Drugs are available before approval in trials or outside. Patients who cannot pay themselves are helped by the corporation. Some funds are given to charity, especially to organisations that advocate for patients’ rights and support them and their families. Celgene corporation supports innovation in medicine not only with its own research but also by giving awards to others. It partners with other similar companies for scientific and bussiness progress as well as with advocacy groups. Their common programs expand healthcare services to previously neglected parts of the world. Celgene’s library of compounds helps other scientists develop treatment for diseases it does not specialise on itself.
It is one of the highest performing companies and its sales are constantly growing. One share costs more than a hundred dollars and is estimated do reach about a hundred and fourty-five after a year, which is even a bit more than it has been in the last year. About five millions a day are sold.